Group 1 - The core viewpoint of the article is that Yabao Chemical (300261.SZ) reported a revenue increase of 6.00% year-on-year for the first three quarters of 2025, amounting to 996 million yuan [1] - The net loss attributable to shareholders of the listed company was 6.9164 million yuan [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 24.8824 million yuan [1] - The basic loss per share was 0.0072 yuan [1]

证券代码：300261 证券简称：雅本化学 公告编号：2025-077 雅本化学股份有限公司 关于 2023 年员工持股计划预留份额分配的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 （一）公司于2023年8月24日召开了第五届董事会第十一次会议和第五届监事会 第十次会议，于2023年9月22日召开2023年第二次临时股东大会分别审议通过了《关 于<雅本化学股份有限公司2023年员工持股计划（草案）>及其摘要的议案》《关于 <雅本化学股份有限公司2023年员工持股计划管理办法>的议案》等相关议案。具体 内 容 详 见 公 司 于 2023 年 8 月 26 日 、 2023 年 9 月 23 日 刊 登 在 巨 潮 资 讯 网 （www.cninfo.com.cn）上的相关公告。 （二）公司于2023年12月27日召开了第五届董事会第十五次会议和第五届监事 会第十四次会议分别审议了《关于<雅本化学股份有限公司2023年员工持股计划（草 案修订稿）>及其摘要的议案》《关于<雅本化学股份有限公司2023年员工持股计划 管理办法（修订稿）>的议案》。具体内 ...

（一）已审批的对外担保额度预计的情况 证券代码：300261 证券简称：雅本化学 公告编号：2025-078 雅本化学股份有限公司 关于增加 2025 年度担保额度及担保对象的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、担保情况概述 2025 年 1 月 24 日，公司第五届董事会第二十三次（临时）会议和第五届 监事会第二十二次（临时）会议审议通过了《关于公司为子公司提供担保及子 公司互相担保的议案》。为满足子公司的经营发展需要，公司同意为子公司办 理银行授信等业务提供担保。2025 年 2 月 24 日，公司 2025 年第一次临时股东 大会审议通过了上述议案。 2025 年 6 月 16 日，公司第六届董事会第四次（临时）会议和第六届监事 会第四次（临时）会议审议通过了《关于全资子公司向银行申请项目贷款并由 公司提供担保的议案》。为满足子公司的项目建设需要，公司同意为子公司申 请银行项目贷款提供担保。2025 年 7 月 2 日，公司 2025 年第二次临时股东大 会审议通过了上述议案。 （二）本次拟增加担保额度及担保对象的情况 根据公司经营的实 ...

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 雅本化学股份有限公司(以下简称"公司")第六届董事会第七次会议于 2025 年 10 月 27 日上午 10:30 以现场结合通讯方式召开，会议通知已于 2025 年 10 月 17 日 以邮件方式送达全体董事。本次会议应出席董事 9 名，实际出席会议董事 9 名。会 议由公司董事长兼总经理蔡彤先生主持，全体高级管理人员列席了会议。本次会议 的召集和召开符合《公司法》和《公司章程》的有关规定。 会议采取记名投票的方式进行表决，经与会的董事充分讨论与审议，会议形成 以下决议： 一、审议通过了《关于<2025 年第三季度报告>的议案》 证券代码：300261 证券简称：雅本化学 公告编号：2025-075 雅本化学股份有限公司 第六届董事会第七次会议决议公告 经审阅，董事会认为公司编制的《2025年第三季度报告》内容真实、准确、完 整地反映了公司2025年前三季度的实际经营情况，不存在任何虚假记载、误导性陈 述或者重大遗漏。本议案已经公司董事会审计委员会审议通过。详见中国证监会指 定信息披露网站刊登的公告。 表决结 ...

Group 1 - The company's Q3 revenue is 335 million, a year-on-year decrease of 4.59% [1] - The net profit for Q3 is 1.752 million, a year-on-year increase of 137.23% [1] - The revenue for the first three quarters is 996 million, a year-on-year increase of 6.00% [1] Group 2 - The net profit for the first three quarters shows a loss of 6.9164 million, a year-on-year decrease of 87.81% [1]

Financial Performance - The company's revenue for Q3 2025 was ¥334,686,849.16, a decrease of 4.59% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥1,752,000.08, an increase of 137.23% year-on-year, while the net profit after deducting non-recurring gains and losses was -¥6,110,957.58, a decrease of 62.13%[5]. - The basic earnings per share for the period was ¥0.0018, up 136.73% year-on-year[5]. - Total operating revenue for the current period reached ¥996,357,916.07, an increase of 5.0% compared to ¥939,956,746.25 in the previous period[20]. - The net profit for the current period was a loss of ¥12,777,476.47, an improvement from a loss of ¥55,695,104.00 in the previous period[21]. - The net profit attributable to the parent company was -6,916,421.61 CNY, compared to -56,719,680.51 CNY in the previous period[22]. - The total comprehensive income amounted to -9,833,502.10 CNY, down from -56,430,109.52 CNY year-over-year[22]. - The basic and diluted earnings per share were both -0.0072 CNY, compared to -0.0589 CNY in the previous period[22]. Assets and Liabilities - The total assets at the end of the reporting period were ¥4,145,198,667.21, reflecting a 3.14% increase from the end of the previous year[5]. - The total assets of the company increased to ¥4,145,198,667.21 from ¥4,019,170,670.70, marking a growth of 3.1%[17]. - Current liabilities rose to ¥1,774,722,283.44, up from ¥1,558,601,363.22, representing an increase of 13.8%[17]. - The total liabilities of the company increased to ¥2,011,507,122.69 from ¥1,875,453,209.03, reflecting a growth of 7.2%[17]. - The company's total equity decreased to ¥2,133,691,544.52 from ¥2,143,717,461.67, a decline of 0.5%[17]. Cash Flow - Cash flow from operating activities showed a net inflow of ¥5,039,810.55, a significant decrease of 94.44% compared to the previous year[5]. - Operating cash flow generated was 5,039,810.55 CNY, a significant decrease from 90,596,629.86 CNY in the previous period[24]. - Cash inflow from operating activities totaled 965,813,689.67 CNY, compared to 927,195,314.12 CNY last year[24]. - Cash outflow from operating activities was 960,773,879.12 CNY, up from 836,598,684.26 CNY in the previous period[24]. - Investment activities resulted in a net cash outflow of -82,047,974.01 CNY, compared to -88,144,766.95 CNY last year[25]. - Financing activities generated a net cash inflow of 162,729,697.72 CNY, reversing from a net outflow of -4,880,504.53 CNY in the previous period[25]. - The ending cash and cash equivalents balance was 409,464,265.46 CNY, an increase from 227,157,307.20 CNY at the end of the previous period[25]. - The company received 48,133,583.50 CNY in tax refunds, up from 39,729,171.92 CNY last year[24]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 52,662[10]. - The largest shareholder, Ningbo Yaben Holdings Co., Ltd., holds 26.75% of shares, totaling 257,729,839 shares, with 87,600,000 shares pledged[10]. - The second-largest shareholder, Wang Xinya, holds 6.75% of shares, totaling 65,000,350 shares, with 65,000,000 shares pledged[10]. - The total number of shares held by the top 10 shareholders includes significant pledges, indicating potential liquidity risks[10]. - The company has a total of 6,657,225 restricted shares that were released due to executive changes[12]. - The report indicates that there are no other known relationships among shareholders beyond those disclosed[10]. Strategic Initiatives - The company signed a strategic supply agreement with Jiangsu Hengrui Medicine Co., Ltd. on August 1, 2025, to enhance collaboration in pharmaceutical intermediates and active pharmaceutical ingredients[13]. - The company announced the termination of plans to acquire a stake in Gansu Haotian Technology Co., Ltd. on July 30, 2025[13]. - The company is focusing on innovation in the pharmaceutical CDMO business as part of its "2+X" strategy[13]. - The company has a strong emphasis on quality control and technological innovation in its operations[13]. Operational Costs - Total operating costs amounted to ¥1,026,893,621.09, slightly up from ¥1,022,711,059.09, indicating a marginal increase of 0.2%[21]. - Research and development expenses increased significantly to ¥86,247,119.60, up from ¥67,919,076.00, reflecting a growth of 27.0%[21]. Asset Management - The company reported a 334.80% increase in fair value changes, amounting to ¥10,885,655.91, primarily due to changes in other non-current financial assets[8]. - The company experienced a 16541.65% increase in asset disposal gains, totaling ¥9,670,874.25, indicating improved asset management[8]. - The company’s long-term borrowings decreased by 38.67% to ¥128,800,000.00, attributed to repayment efforts[8]. - The company’s contract liabilities increased by 88.67% to ¥15,871,737.09, indicating a rise in advance payments received[8]. - The company’s financial expenses decreased by 58.36% to ¥10,189,085.27, mainly due to the impact of exchange gains and losses[8].

Core Insights - The NMN concept index rose by 0.95%, ranking 10th among concept sectors, with 18 stocks increasing in value, led by Te Yi Pharmaceutical, which hit the daily limit, and other notable gainers including Su Yan Jing Shen, Zhong Sheng Pharmaceutical, and Shuanglu Pharmaceutical, which rose by 5.93%, 5.22%, and 4.42% respectively [1][2] Market Performance - The NMN concept sector saw a net inflow of 181 million yuan from main funds, with 13 stocks receiving net inflows, and 5 stocks exceeding 10 million yuan in net inflow. Te Yi Pharmaceutical topped the list with a net inflow of 215 million yuan, followed by Zhong Sheng Pharmaceutical, De Zhan Health, and Shuanglu Pharmaceutical with net inflows of 51.31 million yuan, 35.94 million yuan, and 14.18 million yuan respectively [2][3] Fund Flow Ratios - Te Yi Pharmaceutical, Yaben Chemical, and De Zhan Health had the highest net inflow ratios, with rates of 17.90%, 11.09%, and 9.59% respectively [3]

10月15日，雅本化学涨1.84%，成交额1.02亿元。两融数据显示，当日雅本化学获融资买入额624.52万 元，融资偿还848.39万元，融资净买入-223.87万元。截至10月15日，雅本化学融资融券余额合计2.34亿 元。 融券方面，雅本化学10月15日融券偿还300.00股，融券卖出300.00股，按当日收盘价计算，卖出金额 2157.00元；融券余量17.46万股，融券余额125.54万元，超过近一年90%分位水平，处于高位。 资料显示，雅本化学股份有限公司位于江苏省太仓市太仓港港口开发区石化区东方东路18号，成立日期 2006年1月13日，上市日期2011年9月6日，公司主营业务涉及农药中间体、医药中间体的研究与开发、 生产、销售。主营业务收入构成为：农药中间体69.58%，医药中间体21.73%，其他(补充)4.15%，环保 产品2.85%，特种化学品1.70%。 截至10月10日，雅本化学股东户数5.30万，较上期减少0.88%；人均流通股17675股，较上期增加 0.89%。2025年1月-6月，雅本化学实现营业收入6.62亿元，同比增长12.31%；归母净利润-866.84万元， 同比增长 ...

（文章来源：证券日报） 证券日报网讯 10月13日晚间，雅本化学发布公告称，公司近日接到实际控制人蔡彤先生及汪新芽女士 的通知，蔡彤先生及汪新芽女士将其持有的部分公司股份办理了股份解除质押业务。本次解除质押股份 数量为80，000，000股。 ...

本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 雅本化学股份有限公司（以下简称"公司"）近日接到实际控制人蔡彤先生 及汪新芽女士的通知，蔡彤先生及汪新芽女士将其持有的部分公司股份办理了股 份解除质押业务，具体事项如下： 二、股东股份累计质押的情况 截至本公告日，上述股东及其一致行动人所持质押股份情况如下： 证券代码：300261 证券简称：雅本化学 公告编号：2025-074 雅本化学股份有限公司 关于实际控制人股份解除质押的公告 特此公告。 雅本化学股份有限公司 董事会 公司控股股东宁波雅本控股有限公司、实际控制人蔡彤先生及汪新芽女士资 信情况良好，具备相应的资金偿付能力，整体质押风险可控，不存在平仓或被强 制过户风险，不会导致公司实际控制权发生变更，不会对公司生产经营、公司治 理等产生实质性影响。公司将持续关注其股份质押变动情况及风险，并及时履行 信息披露义务。敬请投资者注意风险。 四、备查文件 1、股份解除质押证明。 2、中国证券登记结算有限责任公司股份冻结明细。 3、深交所要求的其他文件。 股东名称 是否为控 股股东或 第一大股 东及其一 致行动人 本次解 ...